MEKTOVI for children with adamantinomatous craniopharyngioma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests MEKTOVI® to treat pediatric adamantinomatous craniopharyngioma (a type of brain tumor). It may help shrink or control the tumor after it has come back or grown again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 month and 39 years old at enrollment (at least 12 months old).
- Have confirmed adamantinomatous craniopharyngioma based on pathology or characteristic cyst fluid plus brain imaging.
- Have tumor areas doctors can measure (a “measurable” tumor).
- Have stable neurologic symptoms for at least 7 days before starting, and be able to do daily activities to a certain level (Karnofsky/Lansky score).
- Have recovered from prior treatments and be far enough out from the last radiation, chemotherapy/immunotherapy, antibody medicines, steroids, or surgery.
- Have adequate blood counts and organ health (bone marrow, kidneys, liver, and heart rhythm/QT), and controlled seizures if you have them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Actemra (tocilizumab) to slow or shrink adamantinomatous craniopharyngioma, a brain tumor that can recur after treatment. You may be eligible if you’re within the age range and have measurable tumor on scan, with specific rules about prior therapy and recovery.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Hear when a new Adamantinous Craniopharyngioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.